Hematopoietic loss of KDM6A impairs cardiac recovery in heart failure via epigenetic reprogramming of myeloid cells
10 affiliations
- 1Institute of Cardiovascular Regeneration, Center of Molecular Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany
- 2Cardiopulmonary Institute, Goethe University Frankfurt, Frankfurt am Main, Germany
- 3German Center for Cardiovascular Research (DZHK), Partner site Rhine-Main, Frankfurt am Main, Germany
- 4Institute for Computational Genomic Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany
- 5Department of Medicine, Cardiology, University Hospital Frankfurt, Frankfurt am Main, Germany
- 6Experimental Immunology, Department for Children and Adolescent Medicine, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
- 7Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
- 8Institute of Cardiovascular Physiology, Goethe University, Frankfurt am Main, Germany
- 9Department of Cardiology, TUM University Hospital German Heart Center, School of Medicine and Health, Technical University of Munich, Munich, Germany
- 10Deutsches Zentrum für Herz und Kreislaufforschung (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
Abstract
Clonal hematopoiesis (CH), the expansion of blood cell clones carrying acquired mutations, is an independent risk factor for cardiovascular disease. Although mutations in DNMT3A and TET2 are well studied, the cardiovascular consequences of KDM6A mutations remain unclear. KDM6A is an X-linked histone demethylase that is commonly mutated in patients with heart failure (HF). Here we performed multiomics profiling and functional characterization of mouse models and patient-derived data to show that hematopoietic KDM6A loss impairs cardiac recovery after myocardial infarction (MI). KDM6A deficiency increases myeloid cell recruitment to the injured heart and reprograms monocytes, macrophages and neutrophils toward inflammatory, migratory and glycolytic states. Patients with HF and KDM6A-driven CH show similar pro-inflammatory monocyte signatures. KDM6A-silenced macrophages promote cardiomyocyte hypertrophy and cardiac fibroblast activation. Notably, IL-1β blockade after MI rescued the adverse cardiac phenotype of hematopoietic KDM6A loss. These findings identify KDM6A-driven CH as a driver of immune dysregulation and IL-1β signaling as a potential therapeutic target in CH-associated HF.
Related
- Obesity-Associated Inflammatory Reprogramming Impairs a Granulomatous Response to Leishmania infantum
- Environmental exposures and intergenerational cardiovascular risk: epigenetic reprogramming via parental exercise
- Chromatin compartment shifting is recurrent and associated with epigenetic reprogramming in prostate cancer
- Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells
- DNMT1-Mediated Epigenetic Reprogramming Drives KMT2A Amplifications and Rearrangements
BibTeX
@article{solomonidis2026hematopoietic,
title = {{Hematopoietic loss of KDM6A impairs cardiac recovery in heart failure via epigenetic reprogramming of myeloid cells}},
author = {Emmanouil G. Solomonidis and Dennis Hecker and Mariana Shumliakivska and Julian Leberzammer and Ariane Fischer and Minh-Thuy Katschke and Melanie Bendel and Lara Korth and Bianca Schuhmacher and Laura Rumpf and Simone-Franziska Glaser and Katja Schmitz and Guillermo Luxán and Silke Frenz and Penelope Pennoyer and Annett Wilken-Schmitz and Tina Rasper and Sinan Zimmermann and Franziska Ganß and Evelyn Ullrich and David John and Stefan Guenther and Katalin Pálfi and Lisa M. Weiss and Matthias S. Leisegang and Ralf P. Brandes and Moritz von Scheidt and David M. Leistner and Andreas M. Zeiher and Wesley T. Abplanalp and Mario Looso and Marcel H. Schulz and Stefanie Dimmeler and Sebastian Cremer},
journal = {Nature Cardiovascular Research},
year = {2026},
month = nov,
doi = {10.1038/s44161-026-00887-3},
url = {https://doi.org/10.1038/s44161-026-00887-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Hematopoietic loss of KDM6A impairs cardiac recovery in heart failure via epigenetic reprogramming of myeloid cells
AU - Emmanouil G. Solomonidis
AU - Dennis Hecker
AU - Mariana Shumliakivska
AU - Julian Leberzammer
AU - Ariane Fischer
AU - Minh-Thuy Katschke
AU - Melanie Bendel
AU - Lara Korth
AU - Bianca Schuhmacher
AU - Laura Rumpf
AU - Simone-Franziska Glaser
AU - Katja Schmitz
AU - Guillermo Luxán
AU - Silke Frenz
AU - Penelope Pennoyer
AU - Annett Wilken-Schmitz
AU - Tina Rasper
AU - Sinan Zimmermann
AU - Franziska Ganß
AU - Evelyn Ullrich
AU - David John
AU - Stefan Guenther
AU - Katalin Pálfi
AU - Lisa M. Weiss
AU - Matthias S. Leisegang
AU - Ralf P. Brandes
AU - Moritz von Scheidt
AU - David M. Leistner
AU - Andreas M. Zeiher
AU - Wesley T. Abplanalp
AU - Mario Looso
AU - Marcel H. Schulz
AU - Stefanie Dimmeler
AU - Sebastian Cremer
PY - 2026
DA - 2026/11/03
JO - Nature Cardiovascular Research
DO - 10.1038/s44161-026-00887-3
UR - https://doi.org/10.1038/s44161-026-00887-3
AB - Clonal hematopoiesis (CH), the expansion of blood cell clones carrying acquired mutations, is an independent risk factor for cardiovascular disease. Although mutations in DNMT3A and TET2 are well studied, the cardiovascular consequences of KDM6A mutations remain unclear. KDM6A is an X-linked histone demethylase that is commonly mutated in patients with heart failure (HF). Here we performed multiomics profiling and functional characterization of mouse models and patient-derived data to show that hematopoietic KDM6A loss impairs cardiac recovery after myocardial infarction (MI). KDM6A deficiency increases myeloid cell recruitment to the injured heart and reprograms monocytes, macrophages and neutrophils toward inflammatory, migratory and glycolytic states. Patients with HF and KDM6A-driven CH show similar pro-inflammatory monocyte signatures. KDM6A-silenced macrophages promote cardiomyocyte hypertrophy and cardiac fibroblast activation. Notably, IL-1β blockade after MI rescued the adverse cardiac phenotype of hematopoietic KDM6A loss. These findings identify KDM6A-driven CH as a driver of immune dysregulation and IL-1β signaling as a potential therapeutic target in CH-associated HF.
SN - 2731-0590
ER -